Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Biosimilar Labeling Stance Spurs Preemption Questions

Executive Summary

Whether a biosimilar sponsor may unilaterally make safety-related labeling changes is unclear in light of FDA's decision to require labeling for Sandoz's Zarxio that is almost identical to reference product.


Related Content

FDA Proposes Unilateral Generic Drug Label Changes, Signaling End To Liability Shield
Supreme Court Strengthens Generic Liability Shield; FDA Reg Change Could Create Opening


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts